Back to search results

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

Abroad (travel likely)RecruitingPHASE2

Conditions

Neurofibromatosis Type 2 · Vestibular Schwannoma · Non-vestibular Schwannoma · Meningioma · Ependymoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • UCLA Medical Center, Los Angeles, California, United States

    Contact: Study coordinator (Phioanh (Leia) Nghiemphu, MD) · PNghiemphu@mednet.ucla.edu
    Contact: Principal Investigator (Phioanh (Leia) Nghiemphu, MD)

  • University of Miami, Miami, Florida, United States

    Contact: Study coordinator (Christine Dinh, MD) · CTDinh@med.miami.edu
    Contact: Principal Investigator (Christine Dinh, MD)

  • Indiana University School of Medicine, Indianopolis, Indiana, United States

    Contact: Study coordinator (Steven Rhodes, MD, PhD) · sdrhodes@iu.edu
    Contact: Principal Investigator (Steven Rhodes, MD, PhD)

  • Johns Hopkins Hospital, Baltimore, Maryland, United States

    Contact: Study coordinator (Jaishri Blakeley, MD) · jblakel3@jhmi.edu
    Contact: Principal Investigator (Jaishri Blakeley, MD)

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Scott Plotkin, MD) · splotkin@partners.org · (617) 724-8770
    Contact: Principal Investigator (Scott Plokin, MD)

  • New York University Langone Medical Center, New York, New York, United States

    Contact: Study coordinator (Kaleb Yohay, MD) · Kaleb.Yohay@nyulangone.org
    Contact: Principal Investigator (Kaleb Yohay, MD)
Study leads

  • Scott Plotkin, MD

    Principal Investigator

    Massachusetts General Hospital

View source on ClinicalTrials.gov(opens in a new tab)